Zhongnan Medical Journal Press

Home Results

A total of 16 result was found. Results that relate to Pharmacoeconomic

Pharmacoeconomic evaluation of Huangkui capsule versus losartan potassium tablets in the treatment of IgA nephropathy

Published on Chinese Journal of Pharmacoepidemiology 2023,32(1):02-09.
8323 times 3625 times

Liang-Wen GOU Zhao-Ting GUO Qiong LUO Nan YANG Ming HU

Huangkui capsule Losartan potassium tablets Chronic kidney disease Pharmacoeconomics Cost-utility analysis
Details
Bibliometric analysis of pharmacoeconomics evaluation research in China: based on the Web of Science database

Published on Journal of Mathematical Medicine 2023,36(3):185-193.
6453 times 1606 times

Yu-Liang GUI Shi-Qiang XIANG

Pharmacoeconomics evaluation CiteSpace Bibliometrics Visual analysis
Details
Cost-utility analysis of azacitidine versus decitabine in the treatment of myelodysplastic syndrome

Published on Chinese Journal of Pharmacoepidemiology 2023,32(12):1371-1379.
8254 times 1680 times

La-Ji DANZENG Yong-Gong YANG Si-Liang WANG Meng-Ying LIU

Azacitidine Decitabine Myelodysplastic syndrome Markov model Cost-utility analysis Pharmacoeconomics
Details
Cost-utility analysis of tislelizumab versus sorafenib as first-line treatment for advanced unresectable hepatocellular carcinoma

Published on Frontiers in Pharmaceutical Sciences 2024,27(1):109-116.
6908 times 1566 times

SU Zhan CHE Jinhui PEI Ruifeng

Hepatocellular carcinoma Tislelizumab Sorafenib Partition survival model Pharmacoeconomic analysis
Details
Pharmacoeconomic study of Bailing capsules plus conventional therapy in treating diabetic kidney disease

Published on Chinese Journal of Pharmacoepidemiology 2024,33(3):277-290.
8079 times 1663 times

HE Yumei LI Wei ZHU He HAN Sheng

Bailing capsules Diabetic kidney disease Meta-analysis Cost- effectiveness analysis Pharmacoeconomics
Details
Partitioned survival model of pharmacoeconomics evaluation of oncology therapy in R language

Published on Journal of Mathematical Medicine 2024,37(4):240-251.
13530 times 2254 times

LIU Jiayi LI Wei

R language Pharmacoeconomics evaluation Health economic evaluation Partitioned survival model Oncology treating drugs
Details
Pharmacoeconomic evaluation of glucagon-like peptide-1 receptor agonist combined with metformin in the treatment of type 2 diabetes mellitus

Published on Chinese Journal of Pharmacoepidemiology 2024,33(4):388-401.
9552 times 2256 times

YU Tian LIU Shaohua WEI Anhua GUO Jieru ZHANG Chengliang LIU Dong LIU Zhelong

Glucagon-like peptide-1 receptor agonist Metformin Type 2 diabetes mellitus Cost-utility Markov model Pharmacoeconomics
Details
Pharmacoeconomic evaluation of aflibercept versus conbercept for the treatment of wet age-related macular degeneration

Published on Frontiers in Pharmaceutical Sciences 2024,27(4):655-662.
10402 times 1967 times

LIU Dan ZHANG Bochao ZHANG Jing WANG Juan YUAN Yi GUI Lin CHEN Li

Wet age-related macular degeneration Aflibercept Conbercept Markov model Pharmacoeconomic analysis
Details
Cost-utiliy comparison of ranibizumab or aflibercept in the treatment of diabetic macular edema based on a Markov model

Published on Frontiers in Pharmaceutical Sciences 2024,27(7):1155-1161.
8679 times 1445 times

ZHU Yanxia ZHOU Ruting SHI Tianyan

Diabetic macular edema Aflibercept Ranibizumab Pharmacoeconomics
Details
Pharmacoeconomic evaluation of fluticasone furoate/umeclidinium/ vilanterol powder for inhalation for the treatment of chronic obstructive pulmonary disease

Published on Chinese Journal of Pharmacoepidemiology 2024,33(7):721-730.
9371 times 1687 times

DING Xueru LIU Huimin HE Xiaodong LI Hua LI Zhihao

Fluticasone furoate/umeclidinium/vilanterol Chronic obstructive pulmonary disease Markov model Cost-utility analysis Pharmacoeconomic
Details
Cost-utility analysis of pembrolizumab combined with chemotherapy for advanced malignant pleural mesothelioma

Published on Chinese Journal of Pharmacoepidemiology 2024,33(10):1107-1114.
9015 times 1665 times

HU Yunjia ZOU Keqing HOU Yanhong

Pembrolizumab Chemotherapy Advanced malignant pleural mesothelioma Partitioned survival model Cost-utility analysis Pharmacoeconomic evaluation
Details
Pharmacoeconomic evaluation of third-line treatment of advanced non-small cell lung cancer with anlotinib

Published on Frontiers in Pharmaceutical Sciences 2024,28(4):639-647.
10479 times 1185 times

YUAN Wenjie KANG Shuo WANG Xiaohui GONG Yuan PAN Zhenhua

Anlotinib Pharmacoeconomics Non-small cell lung cancer Cost-utility analysis
Details
Cost-effectiveness analysis of low-dose steriod combined with tacrolimus or cyclophosphamide in the treatment of adult idiopathic membranous nephropathy

Published on Chinese Journal of Pharmacoepidemiology 2025,34(2):175-181.
8778 times 1189 times

GUO Shanshan GUO Li LI Jiandong ZHENG Xijie CHEN Hang

Steroid Tacrolimus Idiopathic membranous nephropathy Decision tree model Pharmacoeconomics
Details
Pharmacoeconomic evaluation of ribociclib plus fulvestrant in second-line treatment of HR+/HER2- advanced breast cancer for postmenopausal women

Published on Chinese Journal of Pharmacoepidemiology 2025,34(6):612-620.
7586 times 1149 times

JIA Caifeng WANG Jie ZHANG Sen WANG Meiqi LI Sainan WANG Mingxia

Ribociclib Fulvestrant Advanced breast cancer Postmenopausal Pharmacoeconomic evaluation Cost-effectiveness analysis
Details
Cost-utility analysis of albumin paclitaxel combined with atezolizumab for the treatment of PD-L1-positive advanced triple-negative breast cancer

Published on Frontiers in Pharmaceutical Sciences 2025,29(7):1179-1185.
6671 times 794 times

HU Xiuping TAN Lunan LI Hongbo YAO Huitao

Albumin paclitaxel Atezolizumab Pharmacoeconomics Cost-utility analysis
Details